Literature DB >> 9798677

FGF-3 and FGF-4 elicit distinct oncogenic properties in mouse mammary myoepithelial cells.

A Hajitou1, E N Baramova, K Bajou, V Noë, E Bruyneel, M Mareel, J Collette, J M Foidart, C M Calberg-Bacq.   

Abstract

Fibroblast Growth Factors 3 (FGF-3) and 4 (FGF-4) were compared for the effects they each exert on EF43 mouse cells. This non-transformed mammary cell line appears to be myoepithelial mainly because it expresses alpha-smooth muscle actin. The EF43 cells were infected with similar vectors that carry either the short fgf-3 sequence (the product of which goes into the secretory pathway), fgf-4 or the selection gene only as control. In syngeneic animals, EF43.fgf-3 cells were tumorigenic only when orthotopically implanted whereas EF43.fgf-4 cells invariably gave rise to aggressive tumors. However, both tumor types were metastatic as evidenced by the blue micrometastases observed when the implanted cells expressed lacZ. In vitro, the FGF-3 producing cells were strongly invasive in matrigel coated chambers whereas the EF43.fgf-4 cells only were invasive in type I-collagen gels. Interestingly, FGF-3 production greatly stimulated the synthesis of pro-MMP-9 (Matrix Metalloprotease-9) and, to a lesser extent, that of pro-MMP-2. FGF-3 also up-regulated the production of plasminogen activators. In contrast, FGF-4 had no effect on these secretions and the medium conditioned by the EF43.fgf-4 cells displayed the largest plasminogen activator-inhibitor activity. These results show that FGF-3 and FGF-4 have distinct mechanisms of action on myoepithelial cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9798677     DOI: 10.1038/sj.onc.1202126

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition.

Authors:  Thomas Bachleitner-Hofmann; Mark Y Sun; Chin-Tung Chen; David Liska; Zhaoshi Zeng; Agnes Viale; Adam B Olshen; Martina Mittlboeck; James G Christensen; Neal Rosen; David B Solit; Martin R Weiser
Journal:  Clin Cancer Res       Date:  2011-01-01       Impact factor: 12.531

2.  Selection of phage-displayed accessible recombinant targeted antibodies (SPARTA): methodology and applications.

Authors:  Sara D'Angelo; Fernanda I Staquicini; Fortunato Ferrara; Daniela I Staquicini; Geetanjali Sharma; Christy A Tarleton; Huynh Nguyen; Leslie A Naranjo; Richard L Sidman; Wadih Arap; Andrew Rm Bradbury; Renata Pasqualini
Journal:  JCI Insight       Date:  2018-05-03

3.  Altered HOX and WNT7A expression in human lung cancer.

Authors:  R Calvo; J West; W Franklin; P Erickson; L Bemis; E Li; B Helfrich; P Bunn; J Roche; E Brambilla; R Rosell; R M Gemmill; H A Drabkin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

4.  A novel gene STYK1/NOK is upregulated in estrogen receptor-alpha negative estrogen receptor-beta positive breast cancer cells following estrogen treatment.

Authors:  K Sean Kimbro; Kaitlin Duschene; Margeret Willard; Jodi-Ann Moore; Shalonda Freeman
Journal:  Mol Biol Rep       Date:  2007-04-06       Impact factor: 2.316

5.  Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes.

Authors:  Andrey S Dobroff; Sara D'Angelo; Bedrich L Eckhardt; Fortunato Ferrara; Daniela I Staquicini; Marina Cardó-Vila; Fernanda I Staquicini; Diana N Nunes; Kisu Kim; Wouter H P Driessen; Amin Hajitou; Lesley C Lomo; Marc Barry; Savitri Krishnamurthy; Aysegul Sahin; Wendy A Woodward; Eric R Prossnitz; Robin L Anderson; Emmanuel Dias-Neto; Ursa A Brown-Glaberman; Melanie E Royce; Naoto T Ueno; Massimo Cristofanilli; Gabriel N Hortobagyi; Serena Marchiò; Juri G Gelovani; Richard L Sidman; Wadih Arap; Renata Pasqualini
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-24       Impact factor: 11.205

6.  Upregulation of miR-31* is negatively associated with recurrent/newly formed oral leukoplakia.

Authors:  Wen Xiao; Zhe-Xuan Bao; Chen-Yang Zhang; Xiao-Yun Zhang; Lin-Jun Shi; Zeng-Tong Zhou; Wei-Wen Jiang
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

7.  Ectodysplasin target gene Fgf20 regulates mammary bud growth and ductal invasion and branching during puberty.

Authors:  Teresa Elo; Päivi H Lindfors; Qiang Lan; Maria Voutilainen; Ewelina Trela; Claes Ohlsson; Sung-Ho Huh; David M Ornitz; Matti Poutanen; Beatrice A Howard; Marja L Mikkola
Journal:  Sci Rep       Date:  2017-07-11       Impact factor: 4.379

8.  Targeting a cell surface vitamin D receptor on tumor-associated macrophages in triple-negative breast cancer.

Authors:  Wadih Arap; Renata Pasqualini; Fernanda I Staquicini; Amin Hajitou; Wouter Hp Driessen; Bettina Proneth; Marina Cardó-Vila; Daniela I Staquicini; Christopher Markosian; Maria Hoh; Mauro Cortez; Anupama Hooda-Nehra; Mohammed Jaloudi; Israel T Silva; Jaqueline Buttura; Diana N Nunes; Emmanuel Dias-Neto; Bedrich Eckhardt; Javier Ruiz-Ramírez; Prashant Dogra; Zhihui Wang; Vittorio Cristini; Martin Trepel; Robin Anderson; Richard L Sidman; Juri G Gelovani; Massimo Cristofanilli; Gabriel N Hortobagyi; Zaver M Bhujwalla; Stephen K Burley
Journal:  Elife       Date:  2021-06-01       Impact factor: 8.140

9.  Association of a FGFR-4 gene polymorphism with bronchopulmonary dysplasia and neonatal respiratory distress.

Authors:  Milad Rezvani; Juliane Wilde; Patricia Vitt; Beena Mailaparambil; Ruth Grychtol; Marcus Krueger; Andrea Heinzmann
Journal:  Dis Markers       Date:  2013-10-31       Impact factor: 3.434

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.